In an exciting development for the field of genetic therapy, Vico Therapeutics has successfully raised $26 million in a recent funding round aimed at accelerating the company鈥檚 pioneering work in RNA modulating therapies. Vico is a biotechnology firm dedicated to developing innovative treatments for patients suffering from severe genetic neurological disorders, with a particular focus on spinocerebellar ataxia types 3 and 1, as well as Huntington鈥檚 disease. The funds will be utilized to further advance Vico's proprietary VICOMER platform, which is designed to create antisense oligonucleotides that effectively modulate or edit RNA to address various genetic defects. This groundbreaking approach holds immense potential for transforming the treatment landscape for these debilitating conditions that currently lack effective therapies. By harnessing the power of RNA modulation, Vico Therapeutics is not only paving the way for targeted treatments but is also inspiring hope for countless patients and their families. As the company continues its mission to improve lives through pioneering biotherapeutics, the support from investors signifies a strong belief in the potential of both the science and the team behind it. For more information on Vico Therapeutics and its innovative initiatives, visit www.vicotx.com.
Vico Therapeutics Secures $26 Million in Seed Funding for RNA Modulating Therapies Advancing Genetic Disorder Treatments
Recently funded 路 $26.0M SeedHealthcare
Get the full Vironexis Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Aisot Technologies Switzerland | Seed | $2.5M | today |
| 2 |  DIMENSION United States | Seed | $1.6M | today |
